Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Jazz Pharmaceuticals excels in Q3 with record sales and growth

Jazz Pharmaceuticals' Q3 2024 performance reflects strong revenue growth and operational resilience, driven by key products and ongoing innovation efforts.
While facing challenges like revenue impact for Rylaze, the company remains focused on normalizing demand and advancing its pipeline programs.
With a solid financial foundation and a strategic focus on high-potential areas, Jazz Pharmaceuticals is well-positioned to capitalize on growth opportunities.
By affirming revenue guidance, investing in innovation, and exploring business development prospects, Jazz Pharmaceuticals demonstrates a commitment to long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

Alexion Pharma

Changyou.com Ltd.

Legg Mason

Navient

Quanta Services

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

6 Low Price-to-Book Value Stocks to Buy in December

Jazz Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.

Stocks To Watch: Jazz Pharmaceuticals Sees Relative Strength Rating Jump To 83

ABIOMED

Align Technology

Broadcom

Domino's Pizza

DexCom

Exact Sciences

MarketAxess Holdings

Netflix

United Rentals

These ten growth stocks saw the highest percentage growth over the last decade, and some remain unknown to investors despite huge increases.

10 Best-Performing Growth Stocks of the 2010s

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Jazz (JAZZ) Up 16.4% Since Last Earnings Report: Can It Continue?

AXA Equitable Holdings Inc

Seaspan

Tenet Healthcare

Although PEG is categorized under value investing, it follows the principles of both growth and value investing.

5 Discounted PEG Stocks for GARP Investors

Shares of IBD 50 stock Jazz Pharmaceuticals dipped Tuesday after Axsome Therapeutics unveiled promising Phase 2 test results for a rival narcolepsy treatment, known by the test name AXS-12.
The post How A Rival Narcolepsy Drug Sent This IBD 50 Stock Tumbling appeared first on Investor's Business Daily.

How A Rival Narcolepsy Drug Sent This IBD 50 Stock Tumbling

Jazz (JAZZ) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love Jazz (JAZZ)

AbbVie

Allergan

Bristol-Myers

Merck

Zoetis

Pharmaceutical stocks rose a single-digit percentage in the first 11 months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.

Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

Mr. Cooper Group Inc

Hibbett Sports

Jones Lang LaSalle

Sonic Automotive

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Buy These 5 Top-Ranked Stocks With Relative Price Strength

Jazz Pharmaceuticals (NASDAQ: JAZZ) is a biopharma company based in Ireland. Almost 75% of company’s revenues come from a single drug – Xyrum – which is used to treat narcolepsy (a daytime sleepiness disorder).

Why Has Jazz Pharma’s Stock Rallied Nearly 20% In A Month?

As of late, it has definitely been a great time to be an investor in Jazz Pharmaceuticals plc (JAZZ).

Jazz Pharmaceuticals plc (JAZZ) Shares March Higher, Can It Continue?

Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.

Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe

Bull of the Day: Jazz Pharma (JAZZ)

Jazz (JAZZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Jazz (JAZZ) Might be Well Poised for a Surge

Deckers Outdoor

Masco

Wheaton Precious Metals

Cimarex Energy

While the overall economy has remained solid, we have had a slowdown in manufacturing over the past year.

Merrill Lynch Has 5 Stocks to Buy for a 2020 Jump in the ISM Index

Here is Why Growth Investors Should Buy Jazz (JAZZ) Now

Anixter

KB Home

Lithia Motors

Check out these five high earnings yield stocks for a powerful portfolio.

Bet on These 5 High Earnings Yield Stocks - to Book Profits

Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.

Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales

Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q3 2019 Results - Earnings Call Transcript

Jazz (JAZZ) delivered earnings and revenue surprises of 14.21% and 2.87%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Surpass Estimates

Catalent

Mylan

Regeneron Pharmaceuticals

Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

Alaska Air Group

Guess?

Koppers

Here are five stocks with high earnings yield that can be picked for a solid portfolio.

Invest in These 5 High Earnings Yield Stocks Right Away

GlaxoSmithKline

Incyte

Vertex Pharmaceuticals

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.

5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Jazz (JAZZ)

News for Jazz Pharmaceuticals Stock (JAZZ)